Skip to content
lifestyle.mmminimal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AgomAb Therapeutics N.V.
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
Agomab Announces Pricing of Initial Public Offering
February 11, 2026
←
Previous Page
1
2